Advanced search
Publication Cover
Acta Oncologica Volume 49, 2010 - Issue 1
Journal homepage
798
Views
5
CrossRef citations to date
0
Altmetric
LETTER TO THE EDITOR

Sorafenib induces partial response in metastatic medullary thyroid carcinoma

Elena Spector Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota, USACorrespondence[email protected]
,
Michael J. Franklin Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA
,
Alexander M. Truskinovsky Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA
&
Arkadiusz Z. Dudek Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA
Pages 105-107 | Received 09 Jun 2009, Accepted 25 Jun 2009, Published online: 26 Jan 2010

References

  • Moley JF. Medullary thyroid cancer. Surg Clin North Am 1995;75:405–20.
  • Ball DW. Medullary thyroid carcinoma. Thyroid cancer. A comprehensive guide to clinical management. Wartofsky L. 2000;42:365.
  • Hong D, Ye L, Gagel R, Chintala L, El Naggar AK, Wright J, . Medullary thyroid cancer: Targeting the RET kinase pathway with sorafenib/tipifarnib. Mol Cancer Ther 2008;7:1001–6. Epub 2008 Apr 29.
  • Mulligan LM, Kwok JBJ, Healey CS, Elsdon MJ, Eng C, Gardner E, . Germline mutation of the ret protoonco-gene in MEN type 2A. Nature 1993;363:458–60.
  • Brierley JD, Tsang RW. External radiation therapy of medullary thyroid cancer. Thyroid cancer. A comprehensive guide to clinical management. Wartofsky L, Van Nostrand D. 2006;72:605–7.
  • Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, . Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008;26:3403–10.
  • Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, . Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26:4714–9. Epub 2008 Jun 9.
  • Lanzi C, Cassinelli G, Nicolini V, Zunino F. Targeting RET for thyroid cancer therapy. Biochem Pharmacol 2009;77:297–309. Epub 2008 Nov 6.
  • Plaza-Menacho I, Mologni L, Sala E, Gambacorti-Passerini C, Magee AI, Links TP, . Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. J Biol Chem 2007;282:29230–40. Epub 2007 Jul 30.
  • Henderson YC, Ahn SH, Kang Y, Clayman GL. Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement. Clin Cancer Res 2008;14:4908–14.
  • Sherman SI. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab 2009.
  • Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, . Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009.
  • Ball DW. Medullary thyroid cancer: Therapeutic targets and molecular markers. Curr Opin Oncol 2007;19:18–23.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.